Rep. Jefferson Shreve Sells Off Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by Defense World Staff on Aug 2nd, 2025

Representative Jefferson Shreve (R-Indiana) recently sold shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Alnylam Pharmaceuticals stock on May 12th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of Hubbell (NYSE:HUBB) on 5/12/2025.
Sold $50,001 – $100,000 in shares of Trane Technologies (NYSE:TT) on 5/12/2025.
Sold $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 5/12/2025.
Sold $50,001 – $100,000 in shares of NiSource (NYSE:NI) on 5/12/2025.
Sold $50,001 – $100,000 in shares of Johnson & Johnson (NYSE:JNJ) on 5/12/2025.
Sold $15,001 – $50,000 in shares of AppLovin (NASDAQ:APP) on 5/12/2025.
Sold $15,001 – $50,000 in shares of Fiserv (NYSE:FI) on 5/12/2025.
Sold $15,001 – $50,000 in shares of CNO Financial Group (NYSE:CNO) on 5/12/2025.
Sold $50,001 – $100,000 in shares of Cboe Global Markets (NASDAQ:CBOE) on 5/12/2025.
Sold $15,001 – $50,000 in shares of Lam Research (NASDAQ:LRCX) on 5/12/2025.

Alnylam Pharmaceuticals Trading Up 2.4%

NASDAQ:ALNY opened at $401.80 on Friday. The company’s 50 day moving average is $318.24 and its 200-day moving average is $278.61. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $402.43. The firm has a market cap of $52.39 billion, a price-to-earnings ratio of -162.67 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 444.38%. The business’s quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.16) earnings per share. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital World Investors lifted its holdings in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock valued at $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Capital Research Global Investors raised its stake in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after acquiring an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after acquiring an additional 33,696 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ALNY. Bank of America raised their price target on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Chardan Capital raised their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a report on Friday. BMO Capital Markets lifted their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 24th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an “equal weight” rating in a research report on Friday. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have assigned a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $392.13.

View Our Latest Report on ALNY

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by company insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.